Immune Responses to RHAMM in Patients with Acute Myeloid Leukemia after Chemotherapy and Allogeneic Stem Cell Transplantation
Figure 3
Longitudinal study of RHAMM-specific CTLs in a patient with AML that received allo-SCT. PBMCs were collected from an AML patient at different time points before or after allo-SCT as indicated and subjected to MLPC. CD8+ T cells showed RHAMM-specific release of IFN- (a) and granzyme B (b) at one time point (30 days prior to transplant) when the patient was in CR. This active T-cell population was lost after allo-SCT and not reconstituted when the patient relapsed. (c) CD8+ T cells were stimulated with RHAMM peptide and stained with respective tetramer. Frequencies of RHAMM-specific CTLs vanished over the time, as detected by flow cytometry. Reported frequencies correspond to the gate of CD3+CD8+ T cells (upper numbers) and to all cells in the lymphocyte gate (lower numbers).
